Procter & Gamble officer Paul Gama gave notice of a proposed sale of 14,623 common shares, with an aggregate market value of $2,306,558.91. The approximate sale date is October 23, 2026, and Morgan Stanley Smith Barney LLC is listed as broker. The notice also reports prior sales of 2,225 shares on October 5, 2026, and 3,396 shares on August 20, 2026.
Procter & Gamble Co.’s notice identifies Shailesh G. Jejurikar as proposing to sell 35,000 common shares on October 23, 2026, in an exercise-and-sale-of-stock-option transaction through Morgan Stanley Smith Barney LLC. The stated aggregate market value is $5,520,725.00, based on the average of the high and low prices on October 21, 2026. The notice states that the option acquisition and payment dates will be the same.
Procter & Gamble Co. officer Balaji Purushothaman reported a proposed sale of 4,181 common shares, with an approximate sale date of October 23, 2026. The notice lists Morgan Stanley Smith Barney LLC as broker and an aggregate market value of $659,490.04. It also reports a prior sale by Balaji Purushothaman of 2,019 shares for $290,312.01 on August 20, 2026, during the preceding three months.
The Procter & Gamble Company (PG) reported net sales of $23.276 billion for the three months ended September 30, 2026, up 4% from $22.386 billion a year earlier. Net earnings were $4.757 billion, down 1%, while diluted earnings per share rose 1% to $1.97. Operating cash flow increased $359 million to $5.767 billion; free cash flow was $4.401 billion. Net sales increased across all five reporting segments, from 3% in Health Care and Baby, Feminine & Family Care to 6% in Beauty.
Gross margin declined 160 basis points to 49.8%, as higher commodity costs and product and packaging investments were partly offset by productivity savings. P&G incurred $192 million of restructuring charges during the quarter under a plan expecting approximately $2.0 billion in before-tax costs over two years and up to 7,000 non-manufacturing overhead reductions by the end of fiscal 2027. On October 1, 2026, P&G completed its $3.9 billion all-cash acquisition of Thorne, which will join Personal Health Care; its results are not material to P&G. The company expects to reduce outstanding shares through direct share repurchases at a value of approximately $5.0 billion in fiscal year 2027.
Procter & Gamble (PG) officer Sundar G. Raman gave notice of an intended sale of 38,253 common shares, with an approximate sale date of October 23, 2026. The notice describes the transaction as an exercise and sale of a stock option and lists an aggregate market value of $6,033,836.96, based on the average of the high and low share prices on October 21, 2026. Morgan Stanley Smith Barney LLC is listed as broker. Raman also reported selling 3,435 common shares on August 21, 2026, during the preceding three months, with an aggregate market value of $491,273.70.
The Procter & Gamble Company (PG) reported first-quarter FY 2027 organic sales growth of 4.0% for the quarter ended September 30, 2026, with organic volume up 2.4%; all 10 product categories and all six regions recorded organic sales growth. Core EPS was $2.00, up 1% from the prior year, while currency-neutral Core EPS was $1.99, in line with the prior year. Free cash flow productivity was 93%. Core gross margin was 50.0%, down 150 basis points, and core operating margin was 25.9%, down 80 basis points, versus the prior year.
FY 2027 guidance is 1% to 3% organic sales growth, 2% to 4% net sales growth, 0% to 3% Core EPS growth and 1% to 5% all-in EPS growth. The outlook includes a $1.4 billion after-tax impact from higher energy, transportation and raw material costs, plus after-tax headwinds of $50 million from foreign exchange, $300 million from higher net interest expense and $150 million from lower non-operating income. P&G expects cost headwinds to increase in the next few quarters. FY 2027 guidance also lists dividends of more than $10 billion and approximately $5 billion in direct share repurchases.
The Procter & Gamble Company (PG) reported fiscal 2027 first-quarter net sales of $23.3 billion, up 4% year over year; organic sales also increased 4%. Diluted EPS was $1.97 and Core EPS was $2.00, each up 1%. Operating cash flow was $5.8 billion, and P&G returned $3.9 billion through dividends and share repurchases.
Reported gross margin declined 160 basis points and reported operating margin declined 70 basis points year over year. Higher commodity costs and product reinvestments contributed to lower core gross margin, partly offset by productivity savings and increased pricing. P&G cited a combined fiscal 2027 headwind of $0.79 per share from commodities, net interest expense, lower non-operating income and foreign exchange, equal to an 11% drag on Core EPS growth.
For fiscal 2027, P&G updated all-in sales growth guidance to 2% to 4%, reflecting the Thorne acquisition as of October 1, 2026, and maintained organic sales growth guidance of 1% to 3%. It maintained diluted EPS growth guidance of 1% to 5% and Core EPS growth guidance from in-line to 3%, or $6.89 to $7.11 per share.
The Procter & Gamble Company (PG) reported final results from its October 13, 2026 annual shareholder meeting. Shareholders elected the board nominees to one-year terms, ratified the independent registered public accounting firm, and approved executive compensation in an advisory vote.
The executive-compensation vote received 1,514,086,600 votes for and 138,017,439 votes against. Shareholders rejected proposals to lower the special-meeting threshold, set eligibility thresholds for shareholder-proposal proponents, and require annual reporting on charitable contributions. The special-meeting proposal received 608,496,499 votes for and 1,043,653,976 votes against.
The Procter & Gamble Company (PG) filed a shelf registration covering debt securities it may sell from time to time in one or more offerings. Each offering’s amount, price, maturity, interest rate and other terms will be described in a prospectus supplement. The securities are unsecured obligations under the indenture; unless a supplement indicates otherwise, net proceeds will be used for general corporate purposes. PG may sell the securities directly or through underwriters, agents or dealers.
The Procter & Gamble Company registered 8,000,000 shares of common stock for sale to Direct Stock Purchase Plan participants from time to time after the registration statement’s effective date. Participants may make initial, recurring or one-time cash investments, reinvest all or part of dividends, or receive dividends in cash. Purchases are made in the open market by the Plan Administrator, and P&G states it will not receive proceeds under the Program.
Minimum investments are $250.00 for a new investor’s initial purchase, $50.00 for one-time or recurring optional cash investments, and $10.00 per employee payroll deduction. The maximum cash investment is $6,000,000.00 per calendar year. Optional cash investments are invested within five trading days and no later than 35 trading days, except where postponement is necessary to comply with securities laws. The purchase price is the weighted average price per share for the investment date, plus brokerage charges and applicable transaction fees.